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Tumors derived from rat LA7 cancer stem cells (CSCs) contain a
hierarchy of cells with different capacities to generate self-renew-
ing spheres and tubules serially ex vivo and to evoke tumors in
vivo. We isolated two morphologically distinct cell types with
distinct tumorigenic potential from LA7-evoked tumors: cells with
polygonal morphology that are characterized by expression of
p21/WAF1 and p63 and display hallmarks of CSCs and elongated
epithelial cells, which generate tumors with far less heterogeneity
than LA7 CSCs. Serial transplantation of elongated epithelial cells
results in progressive loss of tumorigenic potential; tumor heter-
ogeneity; CD44, E-cadherin, and epithelial cytokeratin expression
and increased -smooth muscle actin I and vimentin expression. In
contrast, serial transplantation of LA7 CSCs can be performed
indefinitely and results in tumors that maintain their heterogene-
ity, consistent with self-renewal and multilineage differentiation
potential. Collectively, our data show that polygonal cells are CSCs,
whereas epithelial elongated cells are lineage-committed progen-
itors with tumorigenic potential, and suggest that tumor progen-
itors, although lacking indefinite self-renewal potential, neverthe-
less may make a substantial contribution to tumor development.
Because LA7 cells can switch between conditions that favor main-
tenance of pure CSCs vs. differentiation into other tumor cell types,
this cell system provides the opportunity to study factors that
influence CSC self-renewal and differentiation. One factor, p63,
was identified as a key gene regulating the transition between
CSCs and early progenitor cells.
CD133  CD44  mammospheres  tumor-initiating progenitors  p21/WAF1
The cancer stem cell (CSC) hypothesis posits that tumors arederived from mutated stem cells that have retained, or
progenitors that have regained, the stem cell property of cell
self-renewal (1). Only stem cells possess the capacity for indef-
inite self-renewal, whereas lineage-committed progenitor cells
have lost the capacity for self-renewal but still possess extensive
proliferation and differentiation potential (2). The ability to
form and regenerate spheres in culture has been correlated with
self-renewing stem cells and CSCs (3, 4). In addition, it has been
shown that CD24/CD44/LIN cells within human breast
tumors have the capacity to initiate breast tumor growth in
nonobese diabetic severe combined immunodeficient (NOD
SCID) immunocompromised mice (5). The CD44 phenotype
has also been correlated with colon, prostate, and pancreatic
cancer–initiating cells (6–8). However, these studies were unable
to demonstrate tumor outgrowth from a single cell. Because
CSCs could not be isolated and characterized in detail at the
single-cell level, these studies could not resolve whether more
than one type of cell within tumors might retain substantial,
although not limitless, tumorigenicity.
We have used LA7AA10 cells, isolated by Dulbecco from a
mammary adenocarcinoma induced in rat by dimethylbenzan-
thracene to study mammary gland differentiation (9–16) and,
more recently, as a potential CSC model (17). A subclone of
LA7AA10 cells, LA73F12ms (which we designate as stem LA7
[sLA7]) cells have the ability, at the single-cell level, to generate
branched ductal-alveolar–like structures in three-dimensional
(3D) cultures that morphologically and functionally recapitulate
the tubuloalveolar architecture of the mammary tree. Exposure
of sLA7 cells to lactogenic hormones, lipids, or differentiating
agents (e.g., DMSO) results in the formation of dome-shaped
structures representing the cellular changes that occur in the
mammary gland at pregnancy, when alveoli are formed (9–16).
sLA7 cells express CD29 and CD49f, which mark a mammary
stem cell–enriched population in mice (17–19), as well as CD44
and CD133, which are markers for breast, colon, prostate, and
pancreatic CSCs and brainstem cells (5–8, 20–23), and p21/WAF1,
which is a gene involved in the maintenance of the quiescence of
mammary, hematopoietic, and brain stem cells (24–26).
Most importantly, sLA7 cells, at the single-cell level, can
initiate tumors in NOD-SCID mice (17). Such tumors have a
heterogeneous morphology and contain cells with different
capacities to generate self-renewing spheres and 3D organotypic
growth (17). Because most cancers, like sLA7-generated tumors,
are composed of a heterogeneous population of stem and
nonstem cells and tumorigenic and nontumorigenic cells with
marked differences in their capacity to proliferate and differ-
entiate (27), we isolated different cell types from sLA7-
generated tumors based on morphology and determined their
ability to sustain sphere formation, their capacity for 3D orga-
notypic growth, and their tumor-formation potential by trans-
planting them into NOD-SCID mice.
Here, we report that sLA7-generated tumors contain at least
three distinct cell types: polygonal, epithelial elongated, and
mesenchyme-like cells, distinguishable by their morphology and
marker expression. The polygonal and epithelial elongated cells
have different properties in terms of the ability to sustain sphere
formation serially and capacity for 3D organotypic growth and
in terms of tumor-development and tumor-sustaining capacity.
The mesenchyme-like cells were not extensively characterized
because these cells exhibited limited expansion capacity ex vivo
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and no capacity to generate spheres and 3D organotypic growth.
Collectively, our data show that polygonal cells are self-renewing
CSCs and epithelial elongated cells are lineage-committed pro-
genitor cells and that the switch from CSCs to progenitors is
associated with loss of p63.
Results
sLA7 Cells Give Rise to Heterogeneous Tumors.Wegenerated tumors
by injecting 105 sLA7 cells into NOD-SCID mice. Similar to
tumors evoked by a single sLA7, these tumors had a morpho-
logically complex core (Fig. 1 A and B) containing differentiated
structures and functional secretory tubules, as shown by Alcian
blue staining (Fig. 1B). Secretion capacity is indicative of the
presence of terminally differentiated cells (15). Immunological
analysis showed that the tumor core almost completely lacks cells
staining for Ki67, a marker for cell proliferation (Fig. 1E) or
CD44 (Fig. 1K), and has a large number of cytokeratin K14 and
K18 cells (not shown), markers for mammary cell lineage–
specific differentiation (19, 28). The paucity of Ki67 cells
confirms that the core consists predominantly of terminally
differentiated cells. In addition, a complete lack of staining for
p21/WAF1 was observed at the tumor core (Fig. 1H). In contrast,
the peripheral area of the tumors lacked differentiated struc-
tures (Fig. 1C) but contained a high number of Ki67 cells; these
cells constituted an outwardly expanding front of highly prolif-
erative cells (Fig. 1 D and F, arrows). Some cells at the tumor
front stained with p21/WAF1 antibodies [Fig. 1 G and I, arrows,
and supporting information (SI) Fig. S1], but these cells were far
fewer than Ki67 cells (Fig. 1F). Strong CD44 staining was
detected predominantly at the tumor periphery and became
progressively less closer to the tumor core (Fig. 1 J–L, arrows).
Staining of Cytokeratin 14 (K14) and Cytokeratin 18 (K18) was
also observed at the tumor front (not shown). Thus, sLA7 cells
generate heterogeneous tumors characterized by a periphery
defined by an expanding front of Ki67, CD44, and p21/WAF1
cells and a core of differentiated cells lacking p21/WAF1.
Morphologically Different Cell Types from sLA7-Evoked Tumors Have
Different Biological Properties. sLA7 cells can, at the single-cell
level, serially and indefinitely sustain sphere formation and have
high capacity for 3D organotypic growth (17). Serial regenera-
tion of sphere and tubule formation was demonstrated using an
assay in which single cells from a sphere or tubule are able to
generate second and later generations of new spheres or new
tubules clonally (17). We showed that the intrinsic capacity to
sustain sphere formation is an indication that sLA7 cells can
clonally maintain the capacity for trilineage differentiation and
mammary 3D organotypic growth (17). We therefore used the
capacity for sphere sustainability as a criterion, combined with
morphological phenotype and marker expression, to character-
ize cells isolated from sLA7-derived tumors.
Cells from a tumor generated by 105 sLA7 were plated at low
density to isolate single-cell–derived colonies. The characteris-
tics of the various colonies were then determined. Three mor-
phologically distinct cell types were distinguishable microscop-
ically. A small number of colonies contained cells with a
polygonal morphology similar to that of the parental sLA7 cells
(Fig. S2). Single colonies of polygonal cells growing as holo-
clones [a phenotype associated with self-renewing keratinocytes
and prostate carcinoma cells (29, 30)] were isolated and cultured
to generate cell lines and tested for the expression of a variety
of markers, including CD29, CD49f, CD44, CD133, p21/WAF1,
K14, and K18. Expression of E-Cadherin and p63 was also tested
because both have been correlated with the maintenance of the
undifferentiated state of mammary and skin stem cells (24, 31)
and because p63 was found expressed in sLA7 cells and down-
regulated in DMSO-differentiated sLA7 cells (I.Z. and R.D.,
unpublished data). All the cell lines derived from the polygonal
cells, like the parental sLA7, expressed CD29, CD49f, CD44,
CD133, p21/WAF1, E-Cadherin, and p63, and they lacked keratin
14 and 18 expression (not shown). Cells from each cell line could
also serially generate and sustain sphere formation (for at least
10 passages) and tubule formation ex vivo (for at least 5 passages)
and had trilineage differentiation potential (not shown).
We chose one polygonal cell line that met all the previous
criteria for further studies. Like sLA7, this cell line (sLA7-
derivative clone 16, Fig. S2A), in addition to CD29, CD49f, and
CD133 (all not shown), expressed E-Cadherin (Fig. S2B), p21/
WAF1 (Fig. S2C), p63 (Fig. S2D), and CD44 (Fig. S2E), and it had
an extensive capacity to proliferate in vitro (30 passages) and, at
the single-cell level, to serially generate and sustain spheres (Fig.
S2F), tubules (Fig. S2G), cysts (not shown), and domes (Fig.
S2H). Cysts and domes recapitulate some aspects of alveolo-
genesis in vitro (15). Like sLA7, this cell line lacks expression of
keratins 14 (Fig. S2C) and 18 (not shown), as determined by
immunohistochemistry and confirmed by Western blot analysis
(not shown). Because this cell line had many of the character-
istics of sLA7 cells, we designated it as LA7 stem-like (LA7SL)
to distinguish it from the sLA7 line.
We also observed colonies composed of two other morpho-
logically distinct cell types: mesenchyme-like and epithelial
elongated cells. Mesenchyme-like colonies (designated as
LA7ML, Fig. S2I) had a limited proliferative capacity ex vivo
Fig. 1. Staining of a tumor generated by 100,000 sLA7 cells. H&E staining:
panorama (arrow, core of tumor) (A), core (B) (Inset: lumen staining of
secreted proteins), and periphery (C). Antibody staining for Ki67: panorama
(D), core (E), and periphery (F). Staining for p21/WAF1: periphery (arrow,
p21/WAF1 cells) (G), core (H), and periphery (arrow, p21/WAF1 cells) (I).
Staining for CD44: panorama (J), core (K), and periphery (L). Arrows indicate
tumor front. (Magnifications: A, X2.5; D, G, and J, X5; H, K, F, and L, X20; B, C,
and E, X40; B (Inset), X60.)
Zucchi et al. PNAS  November 4, 2008  vol. 105  no. 44  16941
CE
LL
BI
O
LO
G
Y
(three to five passages) and could not form tubules, cysts, or
domes (not shown). When cultured in nonadherent conditions,
LA7ML formed disorganized aggregates instead of spheres (Fig.
S2 J). LA7ML cells (analyzed at passage two to three) expressed
CD29, CD49f, CD133, and CD44, and lacked p21/WAF1, p63,
E-Cadherin, K14, and K18 expression (all not shown).
Elongated epithelial colonies (designated as LA7E) derived
from single cells were individually collected and cultured for 2
passages. Although only one culture, LA7E12 (clone 12), is
shown as an example (Fig. S2K), all cultures tested expressed
CD29, CD49f, and CD133 (all not shown); K14 (Fig. S2L); CD44
(Fig. S2N); and E-Cadherin (Fig. S2O), and they lacked p21/
WAF1 (Fig. S2 L and M), K18 (Fig. S2M), and p63 (not shown)
expression. Like LA7SL cells, LA7E cultures showed extensive
capacity for ex vivo proliferation (for at least 30 passages) and
could form spheres (Fig. S2P) and tubules (Fig. S2Q). Unlike
LA7SL cells, however, LA7E cultures could not sustain sphere
or tubule formation for more than 1–3 passages.
To assess the tumorigenicity of the morphologically distinct
cell types, we carried out transplantation studies using 100 cells
obtained from combined cultures showing the same properties
of LA7E or LA7ML cells, respectively, and 100 cells derived
from a single LA7SL holoclone. Injection of 100 LA7ML cells
resulted in no palpable tumors out of 12 fat pads at day 90 (not
shown). Injection of LA7SL or LA7E at day 90 resulted in five
and four tumors, respectively (ranging in size from 100–300
mm3), out of 6 fat pads injected for each case (not shown).
To assess the tumor-renewing capacity of LA7SL and LA7E
cells, we performed serial transplantation studies using 100 LA7
polygonal or 100 LA7 epithelial elongated cells isolated from a
tumor generated from 100 parental sLA7 cells (Figs. S3, S4A,
and S5). The tumorigenicity of the LA7ML cells was not
extensively evaluated because, as indicated previously, these cells
exhibited only limited expansion capacity ex vivo. At each tumor
generation, LA7 polygonal and LA7 epithelial elongated cells
were isolated by morphology and then characterized for marker
expression, sphere and 3D organotypic growth sustainability,
and trilineage differentiation potential. A unique pair of primers
that amplify different size fragments for mouse (300 bp) and rat
(1100 bp) genomic DNA was used to confirm by PCR that
LA7SL, LA7E, and LA7ML cells were rat cells free of mouse
cells (Fig. S4B).
Serial transplantation of the polygonal cells was performed as
follows: 100 LA7SL1 cell injection (LA7SL1 cells were isolated
from a single holoclone obtained from a first-generation tumor
seeded by injecting 100 sLA7 cells; Figs. S3, S4A, and S5)
resulted in a second-generation tumor from which LA7SL2 cells
were isolated and selected. Then, 100 LA7SL2 cells were used to
obtain third-generation tumors, and 100 LA7SL3 cells selected
from a third-generation tumor were used to make the fourth-
generation tumor; 100 LA7SL4 cells, selected from a fourth-
generation tumor gave rise to fifth-generation tumors (Figs. S4A
and S5). At each serial transplantation, a holoclone of LA7SL
type was isolated and selected using the criteria previously
described. sLA7 (parental) or LA7SL1 (first generation) cell
injection resulted in four and five tumors out of six fat pads for
each cell type (Figs. S3, S4A, and S5). LA7SL2, LA7SL3, or
LA7SL4 resulted in five, four, and five tumors, respectively, out
of six fat pads injected in each case. All tumors generated from
injection of LA7SL-derived cells were structurally identical to
the tumors generated by sLA7 cells, exhibiting a heterogeneous
core with functional tubules (Fig. 2 A and B) and K14- and
K18-expressing cells detected at the tumor core and periphery
(Fig. 2. C–F, respectively). E-Cadherin cells were localized
predominantly at the tumor periphery of all LA7SL-generated
tumors, as shown for LA7SL1- (Fig. 2G) and sLA7- (Fig. 2H)
generated tumors. Furthermore, p21/WAF1 (not shown) and p63
staining (shown for the sLA7-generated tumor in Fig. 2I) were
localized exclusively to the expanding tumor periphery.
Because polygonal cells gave rise to tumors (for at least five
generations) that apparently maintain the same differentiative
capacity (as assessed by morphology and marker expression) and
from which polygonal cells with the same properties can be
reisolated, we conclude that they are CSCs.Moreover, these cells
appear to be enriched at the edges of the tumor, where they may
drive tumor expansion.
Epithelial Elongated Cells Have Tumor-Initiating but Not Tumor Self-
Renewal Capacity. Second-generation tumors were initiated using
100 LA7E1 cells obtained from epithelial elongated cells isolated
and selected (as described for LA7E) from a first-generation
tumor seeded with 100 sLA7 cells (Figs. S3, S4A, and S5). We
carried out serial transplantations of the epithelial elongated
cells using an analogous approach to that described previously
for LA7SL-derived cells. Injection of LA7E1 (second genera-
tion) or LA7E2 (third generation) resulted in four and three
tumors, respectively, out of 6 fat pads injected in each case (Figs.
S3, S4A, and S5). Injection of LA7E3 (fourth generation)
resulted in no palpable tumors out of 12 fat pads injected at day
90. Therefore, 100 LA7E1 cells could give rise to tumors for two
generations but thereafter lost their tumorigenic capacity.
All the LA7E1-derived cultures expressed CD29, CD49f,
CD44, CD133, K14, and E-Cadherin but lacked p21/WAF1, p63,
and K18 expression and could initiate but not sustain sphere or
tubule formation for more than one to three passages (not
shown).
In contrast to LA7E1, all LA7E2 and LA7E3 colonies, in
addition to lacking expression of p21/WAF, p63, and K18, lacked
expression of E-Cadherin andK14 and had no capacity to initiate
sphere or tubule formation (not shown).
Fig. 2. Staining of a tumor generated by LA7SL1. (A) H&E staining, core. (B)
Alcian blue staining of tubule-secreted proteins. Antibody staining for: K14,
core (C); K18, core (D); K14, periphery (E); K18, periphery (F); and E-Cadherin,
panorama (G). (H) E-Cadherin antibody staining of a tumor generated by 100
sLA7 cells (periphery). (I) p63 antibody stainingof tumorgeneratedby105 cells
periphery (arrow, p63 cells). (Magnifications:G, X5; F and I, X10;A,D, E, and
H, X20; B and C, X40.)
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Serially Isolated and Transplanted Epithelial Elongated Cells Show
Progressive Loss of Tumor Heterogeneity. Second-generation tu-
mors derived from LA7E1 cells had central and peripheral areas
that, compared with tumors generated by sLA7 (or LA7SL) cells,
were more homogeneous (Fig. 3 A and B). This loss of tumor
heterogeneity is in agreement with the ex vivo results showing
that although LA7E1 cells have an extensive capacity to prolif-
erate, they do not have sphere or 3D organotypic growth-
regenerating properties.
In contrast to tumors generated by sLA7 or LA7SL tumors, in
LA7E1-derived tumors, Ki67 cells were found at the tumor
core and periphery (Fig. 3 C and D); staining for K14 was
confined to the tumor core (Fig. 3E), and staining for p63 was
not detected (not shown). Also, in contrast to sLA7- or LA7SL-
generated tumors in which strong staining for E-Cadherin (Fig.
2G and H) and CD44 (Fig. 1 J and L) was detected at the tumor
periphery, in the LA7E1-generated tumors, staining for E-
Cadherin (Fig. 3F) and CD44 (Fig. 3G) was not detected at the
periphery but was confined to the core (not shown).
To better characterize second-generation tumors derived
from LA7E1 cells, we carried out immunostaining for two
additional markers, vimentin and -smooth actin muscle I
(-SMAI), which are often associated with loss of expression of
K14 in committed transitional cells (32). Notably, there was a
marked increase in the number of vimentin-expressing cells in
second-generation LA7E1 tumors (Fig. 3H) compared with
second-generation tumors derived from sLA7 cells (not shown).
Moreover, -SMAI, which was not significantly detected in
sLA7-derived tumors (not shown), was observed at the periphery
of the second generation of LA7E1 tumors (Fig. 3I).
The third-generation tumors had central (Fig. S6A) and
peripheral (not shown) areas characterized by a complete loss of
heterogeneity, with no structural complexity or differentiated
structures. Such tumors showed high and homogeneous Ki67
staining throughout (Fig. S6B, core [periphery not shown]), and
in contrast to second-generation tumors obtained by LA7E1,
K14 (Fig. S6C), E-Cadherin (not shown), and CD44 (Fig. S6D)
staining was not observed. The high number of cells expressing
Ki67 throughout the tumor may correlate with the higher slopes
of the tumor growth curve observed in the third-generation
tumors as compared with the second-generation tumors (see Fig.
S3). Also, compared with LA7E1-derived tumors, increased
numbers of vimentin- (Fig. S6E) and -SMAI– (Fig. S6F)
expressing cells were observed.
Thus, although LA7E1 cells retained substantial ex vivo pro-
liferative capacity, their ability to self-renew, in addition to their
differentiative potential, was much more restricted than that of
LA7SL cells. Hence, we suggest that LA7E1 cells are lineage-
committed progenitor cells with significant but not indefinite cell
proliferation and tumorigenic capacity (as opposed to CSCs).
p63, a Key Regulatory Gene in the Switch Between sLA7 and LA7E1.
Our data demonstrate that the LA7E1 early progenitor cells
have many functional properties similar to sLA7 CSCs, including
the ability to generate mammospheres and tubules for one to
three passages. Our data also show that the LA7E1 cells are
indistinguishable from the sLA7 CSCs in terms of the expression
of the stem cell markers CD44 and CD133, because sLA7,
LA7E1, LA7E2, and LA7E3 all express CD133 (Fig. S4A);
although LA7E2 and LA7E3 do not express CD44 mRNA (Fig.
S7A), all or nearly all sLA7 and LA7E1 cells express CD44
protein at the cell surface (Fig. S7B).
Therefore, because we have previously shown that differen-
tiating or differentiated cells derived from sLA7CSCs, although
expressing CD44 and CD133, have limited tumor initiation
capacity (17), we can conclude that CD44 and CD133 expression
is not just restricted to cells with tumor-initiating potential and
that not all tumor-initiating cells express CD44 (e.g., LA7E2). In
agreement with this conclusion, we show that in tumors gener-
ated by sLA7, not all CD44 cells are Ki67 (Fig. 4A, arrow) and
that not all Ki67 cells with tumorigenic potential (e.g., LA7E2,
Fig. 4B) express CD44 (Fig. S7A). From these observations, we
can conclude that CD44 and CD133 are markers that cannot be
used to distinguish sLA7CSCs from progenitor cells with tu-
morigenic potential.
In contrast to CD44 and CD133, p63 protein can be used to
distinguish LA7E1 cells from sLA7 cells (Fig. S8A). Because
sLA7 cells have the capacity for indefinite self-renewal and
tumor regeneration, we hypothesized that p63 is essential for
sLA7 cells to indefinitely regenerate mammospheres. To inves-
tigate whether p63 is involved in the transition of sLA7 to early
progenitor cells, we down-regulated p63 in sLA7 cells using an
antisense oligo approach. sLA7 cells were cultured in nonad-
herent conditions in the presence of p63 antisense oligos for 4
days and monitored for sphere formation potential. Fig. S8B
shows that p63, expressed by sLA7 and sLA7-generated mam-
mospheres, is down-regulated in sLA7 cells treated with anti-
sense p63 and in differentiating/differentiated cells derived from
DMSO-induced sLA7. In sLA7-generated mammospheres, p63
was found expressed in only a few cells (Fig. 5A, arrows). It was
observed that unlike sLA7 cells, p63 antisense oligo-treated
sLA7 cells could generate spheres only for one to three gener-
ations (Fig. 5B). Loss of indefinite sphere formation capacity
suggests that loss of stem cell renewal potential is a consequence
of the down-regulation of p63 protein. Sphere formation inhi-
bition was not attributable to an antiproliferative effect, because
we determined that p63 sense or p63 antisense oligos do not
affect the cell proliferation capacity of the sLA7 cells (Fig. S8C).
Down-Regulation of p63 Results in the Loss of Stem Cell Self-Renewal
and in the Generation of LA7E1 Cells. Transient knockdown of p63
protein also results in the inability of sLA7 to self-renew and to
generate holoclones; p63 antisense oligo-treated sLA7 cells
cultured in non-differentiating conditions gain the ability to
Fig. 3. Staining of a tumor generated by LA7E1 cells. H&E staining: core (A)
and periphery (B). Antibody staining for: Ki67, core (C); Ki67, periphery (D);
K14, core (E); E-Cadherin, periphery (F); CD44, periphery (G); vimentin, pe-
riphery (H); and -SMAI, periphery (I). (Magnifications: A, B, and H, X10; C–G,
and I, X20.)
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generate LA7E1 cells, as shown in Fig. S9A, and are induced to
differentiate, as shown by the formation of domes (Fig. S9B).
Discussion
Previously, we showed that sLA7 cells propagated ex vivo under
standard culture conditions retain the capacity at the single-cell
level to generate and sustain sphere formation indefinitely (17).
Furthermore, sLA7-generated spheres have trilineage differen-
tiation potential as well as significant capacity for ex vivo 3D
mammary organotypic growth (17). Here, we have shown that
sLA7-generated tumors contain a hierarchy of cells with differ-
ent capacities to generate self-renewing spheres and tubules
serially.
We have further characterized this unique cell system by
isolating three distinct types of cells from sLA7-generated
tumors that differ in morphology, immunophenotype, and their
ability to sustain sphere and tumor formation. Mesenchyme-like
cells have limited ex vivo proliferative capacity and lack sphere-
forming ability and tumorigenicity. PCR analysis confirms that
the LA7ML cells are derived from sLA7 rather than reactive host
stromal cells (Fig. S4B). Presumably, they reflect cells that have
undergone an irreversible epithelial-mesenchymal transition.
Although such cells may help to support the tumor mass (e.g., by
directly providing trophic factors or promoting angiogenesis),
they cannot drive further tumor expansion (33).
Polygonal (LA7SL) and elongated epithelial (LA7E) cells, like
the sLA7 CSCs from which they derive, express the normal
mammary stem cell markers CD29 and CD49f and the putative
CSC markers CD133 and CD44. LA7SL cells, like sLA7 CSCs,
are characterized by expression of p21/WAF1 and p63, both of
which are involved in stem cell maintenance, generate hetero-
geneous adenocarcinomas similar to the tumors from which they
were originally derived, and can serially regenerate such tumors
for five successive generations. In addition to displaying mor-
phological fidelity, LA7SL-derived tumors continue to display
the same immunophenotype as parental sLA7-derived tumors
(Figs. 2 and S4A). Furthermore, LA7SL cells isolated at each
tumor generation on the basis of their polygonal morphology
retain the capacity to generate spheres, show 3D organotypic
growth, and differentiate into all cell lineages of the mammary
gland.
The first-generation LA7E-type cells (LA7E1), also isolated
from sLA7-generated tumors, are characterized by expression of
K14, CD44, and E-Cadherin and lack of p63 and p21/WAF1
expression. These cells generate tumors with far less complex
differentiated structures; lack p63 expression; and lose expres-
sion of K14, CD44, or E-Cadherin. Tumor heterogeneity and,
ultimately, tumorigenicity itself decline on serial transplantation
of LA7E-type tumor cells. Furthermore, LA7E1 cells can only
generate spheres or give rise to 3D organotypic growth for one
to three passages. Because LA7E1 cells have high proliferative
potential, we performed cell-limiting dilution transplantation
studies and determined that at least 10 cells are required to
generate tumors (data not shown). In contrast to this, it was
previously determined that 1 sLA7 cell is sufficient to generate
a tumor (17), in agreement with the observation that sLA7, but
not LA7E1, cells have the capacity for self-renewal.
Taken together, our data suggest that sLA7 cells, when
maintained ex vivo under undifferentiating culture conditions,
expand as essentially pure cultures of CSCs. When placed in the
appropriate environment (niche), such as sphere-forming cul-
ture conditions or the mammary fat pad, these cells display
substantial differentiative capacity while retaining their self-
renewal potential, both of which are hallmarks of CSCs. In
addition to giving rise to additional CSCs (LA7SL-type cells),
they generate cells that retain substantial proliferative ability
(LA7E-type cells) but that have more restrictive differentiative
Fig. 5. (A) p63 immunostaining of a sphere generated by a single sLA7 cell.
p63 protein is expressed in self-renewing sLA7 mammospheres (arrows, p63
cells). Hoechst nuclear dye 33342 (blue). (B) Down-regulation of p63 in sLA7
results in loss of indefinite sphere-regeneration potential. sLA7 cells were
cultured with no sense oligos p63 (Sp63), antisense p63 (ASp63), or oligos
(control) for 96 h in nonadherent conditions.
Fig. 4. Ki67 and CD44 double-staining of a tumor generated by sLA7 cells.
(A) Antibody staining for Ki67 (nuclear, brown), CD44 (red), and Hoechst
nuclear dye 33342 (blue). (Magnifications: X20; Inset, X40.) (B) Antibody
staining for Ki67 (nuclear, brown) on sLA7, LA7E1, LA7E2, and LA7E3 cells.
(Magnification: X40.)
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capacity and no self-renewal capacity and generate cells that
appear to differentiate terminally.
Our findings have several important implications. Although
LA7E-type cells cannot infinitely self-renew, they still have
substantial proliferative capacity and tumor-initiating potential.
It has been suggested that it might be possible to cure most
tumors simply by ablating CSCs (27). If the proliferative capacity
of most ‘‘tumor progenitors’’ resembles that of LA7E cells, it
seems likely that most tumors presenting clinically with a critical
number of tumor progenitor cells might be lethal even if all CSCs
were killed. We also show that early progenitor cells like LA7E1
are indistinguishable from LA7 CSCs in terms of stem cell
markers CD29, CD49f, CD44, and CD133. In addition, early
progenitor cells have the capacity, although limited, to generate
mammospheres, tubuli, and CD44 and CD44 cells. Our results
provide an alternative explanation as to why different types of
breast tumor–initiating cells (with different cell surfacemarkers)
are observed in tumors that should theoretically be derived from
a single CSC. We suggest that tumor heterogeneity may be
partially attributable to the currently unrecognized contribution
of tumor-initiating progenitor cells to tumor development.
Our research demonstrates that p63 is a key regulator in the
maintenance of ‘‘stemness’’ in sLA7 CSCs, in the ability of CSCs
to regenerate mammospheres indefinitely, and in the transition
of CSCs to early progenitors. In agreement with our results, p63
has recently been shown to be involved in the maintenance of the
skin stem cell pool of epidermal keratinocytes, and its loss is
associated with induction of differentiation (31). Finally, our
data suggest that, at least for this cell system, serial sphere-
forming capacity may represent a valid surrogate for CSC
self-renewal.
We show that although LA7E1 cells lack indefinite self-
renewal and sphere-regenerating capacity, they still have tumor-
initiating potential. We suggest that sphere sustainability is a
property exclusive of cell-renewing stem cells and that the ability
of LA7E1 to form tumors is attributable to their inherent
extensive capacity for cell proliferation.
Materials and Methods
Cells, Media, and 3D Cultures. LA7/3F12ms cells were recently subcloned from
the LA7AA10 cell line (9, 17). LA7/3F12ms, LA7SL, LA7E, and LA7ML cells were
cultured in DMEM as described. 3D cultures were performed using rat tail
collagen as described (17).
Cell Transplantation in NOD-SCID Mice. As described (17), 100,000 or 100 cells
were injected into the fat pad of NOD-SCID mice.
Immunohistochemistry. Cells obtained from tumors or sections from each
tumorbiopsywereprocessed for immunohistochemistry asdescribed (17). The
primary mouse monoclonal antibodies used are listed in SI Experimental
Procedures.
Negative controls were run in parallel with preimmune rabbit serum.
Counterstaining was performed with hematoxylin (17).
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